IL6 and myeloid sarcoma: For instance, levels of both IL-17 and IL-6 were shown to positively correlate with neurological disabilities in MS patients (18), and blockade of IL-6-dependent pathways using an anti-IL-6 receptor antibody limited the development of EAE in mouse models, most likely by counteracting the differentiation and expansion of pathogenic TH17 cells while promoting Treg cell responses (54, 55).